Welcome to our dedicated page for Cingulate news (Ticker: CINGW), a resource for investors and traders seeking the latest updates and insights on Cingulate stock.
Cingulate Inc. develops biopharmaceutical products using its proprietary Precision Timed Release™ (PTR™) drug-delivery platform, with a focus on ADHD and other CNS disorders. CINGW represents Nasdaq-listed warrants exercisable for Cingulate common stock, so recurring company updates center on the operating issuer’s clinical, regulatory, financing, and governance developments.
Company news commonly covers CTx-1301, a once-daily dexmethylphenidate tablet designed for timed drug release across the day, along with pipeline work such as CTx-1302. Recurring themes include FDA submission and review updates under the 505(b)(2) pathway, Phase 3 data presentations, patent activity, commercial manufacturing arrangements, commercialization planning, financial results, private placements, debt exchanges, and board or executive changes.
Cingulate Inc. has priced its initial public offering (IPO) of 4,166,666 shares at $6.00 per share, paired with warrants at the same price. The offering will yield gross proceeds of approximately $25 million, aimed at advancing its clinical products, including CTx-1301 and CTx-1302, focused on ADHD treatment. The shares and warrants are set to trade on Nasdaq under the symbols ‘CING’ and ‘CINGW’ starting December 8, 2021. The transaction is expected to close on December 10, 2021, if standard conditions are met.